Despite the presentation of encouraging study findings with novel immunotherapy-based therapies, long-term outcomes are needed to better understand the magnitude of clinical benefit and many questions remain around off-target toxicity and the identification of patients most likely to respond to treatment
While early-phase findings confirm the efficacy and mild toxicity of radiopharmaceuticals, patient selection and logistical issues limit their integration into broad clinical practice
Data from new clinical trials reported positive results of radioligand therapy over everolimus and sunitinib, and explore the combination of everolimus and somatostatin analogues
The fields of metastatic pancreatic NETs and advanced and low proliferative grade 3 disease tumours move forward
Promising data from a subgroup analysis of the phase III NETTER-2 study support the use of peptide receptor radionuclide therapy in treatment-naïve patients
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Study findings support routine RET-mutation testing for all patients with advanced MTC, but further work is needed to identify predictive markers
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
A Spanish study describes the genomic characterisation of neuroendocrine neoplasms as the first step towards more personalised management
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.